Corporate News

Aiming to be Thailand’s leading producer of upstream, mid-stream and downstream pharmaceutical products, BLC plans to introduce new generics made from high-quality herbs grown by Thai farmers and produced with modern technology that best addresses the specific needs of the aging society and NCDs patients. The company will also invest 825 million baht in increasing pill production capacity to 960 million tablets/year and hopes to achieve 2,000 million baht revenue by 2026.

BLC will also demonstrate its capacity and potential at the region’s largest pharmaceutical trading and conference platform, CPHI South East Asia 2024 held by Informa Markets Thailand from 10-12 July 2027 at the Queen Sirikit National Convention Center.

Ms. Rungphech Chitanuwat, Regional Portfolio Director – ASEAN, Informa Markets and Country General Manager – Philippines, explained that the number of seniors in Thailand expands at 7.5% per year on average. Senior population accounts for 18.3% of the total population in Thailand in 2024 and will increase to 19.7% in 2025, and 21.1% in 2026. By 2050, the country will become a super-aged society as more than 28% of the total population will be seniors. Considering this trend, the need for modern medicine and healthcare products will be increasing, especially for preventive care and NCDs treatment which requires high-quality medicine and products for continuous treatment. The demand from overseas markets, especially Southeast Asian countries, is also rising.

Thai pharmaceutical industry has high potential and widely recognized for its research and development capability and international standard quality. Local companies also have a shared commitment to making the pharmaceutical industry a New S-Curve sector that creates higher economic value and drives Thailand as the medical hub of Southeast Asia, which will generate more income to the country in the future.

CPHI South East Asia 2024 is a fully integrated trading and conference platform for people in the pharmaceutical industry in Southeast Asia. This annual event expects several producers, distributors and innovators in the pharmaceutical and related businesses showcasing innovations, technologies, products and equipment. The event will also put Thailand’s pharmaceutical industry on the world map and enable Thais to have easier access to high-quality pharmaceutical products.

Mr. Suvit Ngampoopun, Chief Executive Officer (CEO), Bangkok Lab and Cosmetics Public Company Limited (BLC), said, the company is a leading pharmaceutical and healthcare product company in Thailand, developing and manufacturing high quality products from local herbs for over a decade. BLC is committed to delivering effective, high-quality and safe Thai herbal products and medicine to consumers. In addition, the company has been seriously supporting the Thai pharmaceutical industry and promoted made in Thailand products. With investment privileges from the Board of Investment, the company continuously improves production standards and services and sustainability. Meanwhile, BLC strongly adheres to its “SMILE” corporate values – Social and environmental responsibility, Moral, Innovation, Loyalty, and Excellence performance.

He explained that more patients are returning to hospitals and clinics after the COVID-19 pandemic, coupled with economic recovery and the development of an ageing society. This has also driven NCDs occurrence. Such a trend also supports the expansion of Thailand’s 200-billion pharmaceutical market.

Considering the future growth potential of the pharmaceutical industry, BLC aims to grow together by focusing on both modern and traditional Thai medicine, and research and development of local herb medicine. The company believes this will increase access to quality medicine among Thai consumers while reducing dependence on imported medicine and ingredients. At the same time, this opens new opportunities for Thai herbal medicine innovations in Thailand and international markets.

The company has invested 825 million baht in a new manufacturing facility, covering a 5,590-square-meter raw material warehouse and an 8,600-square-meter production plant. The new facility will increase BLC’s production capacity by 960 million tablets per year, which also enables the company to achieve 2,000 million baht revenue goal by 2026.

In terms of distribution, BLC distributes pharmaceutical and healthcare products through B2B channels, such as pharmaceutical shops, public and private hospitals, private companies, and retail shops in Thailand and foreign countries, and through B2C channels via hypermarkets, convenience stores and online channels.

Later this year, BLC will participate in the CPHI South East Asia 2024 by showcasing Thai herbal products made from locally grown herbs by Thai farmers and extracted by patented advanced technology that ensures consistency of quality, quantity and environmental friendliness as well as no residual solvent.

BLC will also introduce new generics for the treatment of most frequently found health problems in the aging population and NCDs patients. The company will also promote its contract development and manufacturing organization (CDMO) capability that addresses the different needs of customers with environmentally friendly business operations, renewable energy focus, and emphasis on environmental, social and governance (ESG) practice to support sustainable development.

“We see and strongly believe in the entire industry’s capability. We see a high potential to raise funds in the capital market. This will enable us to further develop our products to cover the entire range of upstream, midstream and downstream products. By leverage on our generics production capability and high-quality herbal medicine, we want to be part of the key driving force that helps Thailand become the medical hub and the center for wellness, medical services, academic and products,” said Suvit.